Gemphire Therapeutics (NASDAQ: GEMP) recently received a number of ratings updates from brokerages and research firms:

  • 10/27/2017 – Gemphire Therapeutics had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $22.00 price target on the stock.
  • 10/25/2017 – Gemphire Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company’s product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan. “
  • 10/23/2017 – Gemphire Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $10.00 price target on the stock. According to Zacks, “Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company’s product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan. “
  • 10/23/2017 – Gemphire Therapeutics had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $31.00 price target on the stock.
  • 10/19/2017 – Gemphire Therapeutics is now covered by analysts at Roth Capital. They set a “buy” rating and a $30.00 price target on the stock.
  • 10/16/2017 – Gemphire Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. They now have a $11.00 price target on the stock. According to Zacks, “Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company’s product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan. “
  • 10/13/2017 – Gemphire Therapeutics had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They wrote, “We believe gemcabene’s 40% hsCRP reduction is very meaningful, especially given that Novartis canikinumab reduced hsCRP and lowered Major Adverse Cardiac Events (MACE). In our view, gemcabene has lowering effects on important biomarkers beyond LDL, including triglycerides and hsCRP, differentiating the drug from competitors. Continue to anticipate positive INDIGO-1 data in 2018 We expect gemcabene to show a statistically significant reduction in triglycerides in the INDIGO-1 study in 2018, providing a major catalyst for shares to move higher. Importantly, many drugs can lower LDL cholesterol, but some have no effect on triglycerides, such as PCSK9 therapies.””
  • 10/10/2017 – Gemphire Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company’s product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan. “

Gemphire Therapeutics (NASDAQ:GEMP) last issued its quarterly earnings data on Monday, August 14th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.28).

Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.

Receive News & Ratings for Gemphire Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.